Fig. 1: B7-H3 is selectively overexpressed in mCRPC.

a mRNA expression of B7-H3 in primary and metastatic prostate cancer (PC). Whole-transcriptome sequencing (WTS) data were obtained and analyzed from MSKCC 2010 (primary PC in gray, n = 131; metastatic PC in red, n = 19). All data are median with 95% CI. Statistical significance was using student t-test. **P < 0.01. b–e mRNA expression of B7-H3, PD-L1, PD-L2, and CTLA-4, respectively, in mCRPC (SU2C, green; SUWC, orange) and normal prostate tissue (GTEX, blue). Whole-transcriptome sequencing (WTS) data were obtained and analyzed from SU2C/PCF (n = 208, mCRPC), SUWC (n = 101, mCRPC), and GTEx (n = 245, benign prostate tissue). Data of other B7 family genes are shown in Supplementary Fig. 2. All data are median with 95% CI. Statistical significance was assessed using one-way ANOVA for multiple comparisons. ****P < 0.0001. f, g Lack of correlation of mRNA expression of B7-H3 and PSMA in mCRPC datasets SU2C/PCF (n = 208, r = 0.0003) and SUWC (n = 101, r = −0.024), respectively. Associations were determined by Pearson correlations. h Percentage of cells expressing B7-H3 (B7-H3 positive, green; B7-H3 negative, gray) before (17.9%) and after (38.5%) enzalutamide treatment. ScRNA-Seq analysis was performed on cells from patient before (n = 112) and after enzalutamide (n = 83) treatment. i GSEA of B7-H3 with functional oncogenic pathways. WTS data of mCRPC datasets SU2C/PCF (n = 208) and SUWC (n = 101) mCRPC were combined for GSEA. NES cutoff value 1.4. NES normalized enrichment score. FDR false discovery rate.